Return to Main Site 617-919-3019
401 Park Drive, 7th Floor East, Boston, MA 02215

TIDO Technology Search



Invention Type

Diagnostic/Prognostic
Information Technology/Software
Medical Device
Other
Research Tool
Therapeutics

Research Area

Allergy/Respiratory/Pulmonary Disease
Anesthesia
Audiology
Cardiovascular/Cardiology
Degenerative Disease
Dermatology
Endocrinology
Gastrointestinal/Nutrition
Genetic Disease
Health Care Management
Immunology
Infectious Disease
Inflammation
Internal Medicine
Metabolic Disease
Musculoskeletal
Neonatology/Pediatric
Neurology/Neuroscience
Oncology/Hematology
Ophthalmology
Orthopedics
Otolaryngology/Audiology
Pain
Pathology
Personalized Medicine
Psychiatric Disease
Radiology
Regenerative Medicine
Reproduction/Ob-Gyn
Stem Cell
Surgery/Wound Healing
Urology
CMCC 2200

Novel age-specific vaccine testing platform

Inventors: Guzman Sanchez-Schmitz, Ofer Levy

Invention Types: Therapeutics, Research Tool

Research Areas: Immunology

Keywords: Assay, Vaccine, Platform

For More Information Contact:  Meyer, Abbie

 

Invention Description:

Vaccines provide safe and effective protection from a multitude of infectious diseases. However, the need for the development of new vaccines persists. This need is most prevalent in neonates and infants whose lack of vaccination leaves them prone to deadly infections. Newly developed vaccines suffer from a low success rate in clinical trials because of preclinical testing conducted on models that provide inaccurate predictions of human immune responses.


Drs. Schmitz and Levy have developed an effective method to model neonatal vaccine responses through the use of an in vitro microphysiologic tissue construct. This novel platform is capable of allowing analyses with human primary, untouched materials instead of animal models. It is designed to use age-specific monocytes to add greater specificity to the model. All of these factors culminate to provide researchers with a better understanding of a vaccine’s impact in neonates and beyond. The effects of adjuvant and vaccine candidates can be readily and more thoroughly tested with this technology, helping to evaluate them at a lower cost.


Proof of concept:

Testing of this technology was confirmed using well-known and routinely prescribed newborn vaccines resulting in the production of active antigen-presenting cells and cytokine secretion patterns which are confirmed with in vivo occurrences.

Applications:

Vaccine development platform that demonstrates the efficacy of new vaccines by accurately modeling their age-specific human response.

Competitive Advantages:

• Accurately represents the physiological functioning of human immune interactions.

• Models cellular environmental responses that are exclusive to neonates and adults.

• Demonstrates cellular reactions for specific human ages.

• Provides unique insight into the human immune response when presented with a new formulation of a vaccine or adjuvant.

• Provides greater accuracy in adjuvant and vaccine testing which decreases the time and money spent on preclinical testing.

Business Opportunity:

Licensing agreement or sponsored research.

Key Publications: Sanchez-Schmitz G, Levy O. Development of newborn and infant vaccines. Sci Transl Med. 2011;3(90):90ps27.

IPStatus: Pat. Pend.